We have continued using data integration methods for a multi-level joint analysis of transcriptomics and proteomics data sets obtained from mouse brains after cerebral ischemia identifying molecules that might be considered as biomarkers & therapeutic targets of ischemic stroke. We have studied the relationship of blood pressure and kidney function in the progression of cognitive decline and cerebrovascular lesions in hypertensive patients, and explored predictive clinical and biological factors of small vessel disease progression considering neuroimaging markers and cognition over time and their relation to stroke. We have also started several nanotechnology projects aiming at improve future treatment of stroke and new therapeutic strategies to improve brain delivery of biomaterials. Finally, we have participated in an international study aiming to update and externally validate the diagnostic criteria across the full spectrum of clinical presentations of cerebral amyloid angiopathy.

Group Leader
Anna Rosell Novel

Principal Investigator (PI)
Mar Hernández-Guillamon, Pilar Delgado, Olga Maisterra, Joan Montaner.

Researchers
Elena Palà, Antoni Palasí, José Álvarez-Sabín

PhD Students
Mercedes Arrúe, Alba Grayston, Anna Bonaterra, Nicolás Rodríguez, Paula Garcia, Daisy Guamán, Laura Ramiro

Lab Technicians
Anna Penalba, Miguel Garcia, Júlia Valor, Kerrie Adrián, Feifei Ma

Nursing and Technical Staff
Jesús Pizzarro, Marcel Lamana, Elvira Chocano

29

PUBLICATIONS

58.6%

%Q1

295

IMPACT FACTOR

10.17

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Charidimou A, Boulouis G, Frosch MP, Baron JC, Pasi M, Albucher JF, Banerjee G, Barbato C, Bonneville F, Brandner S, Calviere L, Caparros F, Casolla B, Cordonnier C, Delisle MB, Deramecourt V, Dichgans M, Gokcal E, Herms J, Hernandez-Guillamon , Jager HR, Jaunmuktane Z, Linn J, Martinez-Ramirez S, Martinez-Saez E, Mawrin C, Montaner J, Moulin S, Olivot JM, Piazza F, Puy L, Raposo N, Rodrigues MA, Roeber S, Romero JR, Samarasekera N, Schneider JA, Schreiber S, Schreiber F, Schwall C, Smith C, Szalardy L, Varlet P, Viguier A, Wardlaw JM, Warren A, Wollenweber FA, Zedde M, van Buchem MA, Gurol ME, Viswanathan A, Al-Shahi Salman R, Smith EE, Werring DJ, Greenberg SM.
The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study.
Lancet Neurol . 2022 Aug;21(8):714-725.
DOI: doi: 10.1016/S1474-4422(22)00208-3.
IF: 59.94

Grayston A, Zhang Y, Garcia-Gabilondo M, Arrue M, Martin A, Kopcansky P, Timko M, Kovac J, Strbak O, Castellote L, Belloli S, Moresco RM, Picchio M, Roig A, Rosell A
Endovascular administration of magnetized nanocarriers targeting brain delivery after stroke.
J Cereb Blood Flow Metab. 2022 Feb;42(2):237-252
DOI: doi: 10.1177/0271678X211028816. Epub 2021 Jul 6.
IF: 6.60

Camacho J, Rabano A, Marazuela P, Bonaterra-Pastra A, Serna G, Moline T, Ramon Y Cajal S, Martinez-Saez E, Hernandez-Guillamon.
Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease.
Brain Pathol. 2022 Jan;32(1):e13016.
DOI: doi: 10.1111/bpa.13016. Epub 2021 Sep 12.
IF: 7.61

Simats A, Ramiro L, Valls R, de Ramon H, Garcia-Rodriguez P, Orset C, Artigas L, Sardon T, Rosell A, Montaner J
Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke.Simats A, Ramiro L, Valls R, de Ramon H, Garcia-Rodriguez P, Orset C, Artigas L, Sardon T, Rosell A, Montaner J
Neurotherapeutics. 2022 Mar;19(2):513-527.
DOI: doi: 10.1007/s13311-022-01203-0.
IF: 6.09

Marazuela P, Paez-Montserrat B, Bonaterra-Pastra A, Sole M, Hernandez-Guillamon.
Impact of Cerebral Amyloid Angiopathy in Two Transgenic Mouse Models of Cerebral beta-Amyloidosis: A Neuropathological Study.
Int J Mol Sci . 2022 Apr 29;23(9):4972.
DOI: doi: 10.3390/ijms23094972.
IF: 6.21

Redes Temáticas RICORS. RICORS-ICTUS-Enfermedades Vascualres Cerebrales.
Principal Investigator: Anna Rosell
Agency: Instituto de Salud Carlos III
Funding: 250,215 €
Period: 2022-2024

Identificación de biomarcadores y dianas terapéuticas para neuroreparación durante la neurorehabilitación tras el ictus.
Principal Investigator: Anna Rosell
Agency: Instituto de Salud Carlos III
Funding: 171,820 €
Period: 2020-2022

PRESTIGE-AF: PREvention of STroke in Intracerebral hemorrhaGE survivors with Atrial Fibrillation.
Principal Investigator: Joan Montaner
Agency: European Comission
Funding: 481,723 €
Period: 2017-2023

Implicaction of proteins associated with vascular beta-amyloid in Cerebral Amyloid Angiopathy.
Principal Investigator: Mar Hernandez Guillamon.
Agency: Instituto de Salud Carlos III
Funding: 169,400 €
Period: 2021-2023

Demencia mixta por Alzheimer y enfermedad cerebrovascular: un estudio clínico y experimental.
Principal Investigator: Pilar Delgado Martínez
Agency: Instituto de Salud Carlos III
Funding: 134,310 €
Period: 2021-2023

DIAGNOSIS MARKERS FOR ATRIAL FIBRILLATION
Priority Number: PCT/EP2020/061467
Priority Date: 24/04/2020
Applicants: VHIR

METHOD FOR SELECTING A PATIENT FOR A REPERFUSION THERAPY
Priority Number: PCT/EP2020/063726
Priority Date: 15/05/2020
Applicants: VHIR

METHODS AND COMPOSITIONS FOR TREATING ISCHAEMIA IN A SUBJECT
Priority Number: EP21382021.0
Priority Date: 15/01/2021
Applicants: 90% VHIR, 10% ANAXOMICS

BIOMARKERS FOR STROKE PROGNOSIS
Priority Number: PCT/EP2020/070152
Priority Date: 16/07/2020
Applicants: VHIR

MARKERS AND THEIR USE IN BRAIN INJURY
Priority Number: EP20382889.2
Priority Date: 8/10/2020
Applicants: 50% University Geneva/ 50% VHIR

eCOREs